Categories: News

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results on Monday, May 6, 2024, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, May 6, 2024, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/50407.

For those unable to listen to the live webcast, a replay will be available for 30 days on the Investors section of the Company’s website at www.krystalbio.com.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACT
Investors and Media:                                                             
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com

Staff

Recent Posts

In the Age of Automation, Human Collaboration Still Counts: Survey Highlights Critical Role of Medical Lab Staff, Influences on Doctors’ Orders

Empowered patients, inadequate healthcare coverage, and systemic pressure are factors influencing doctors’ test orders and…

52 minutes ago

In the Age of Automation, Human Collaboration Still Counts: Survey Highlights Critical Role of Medical Lab Staff, Influences on Doctors’ Orders

Empowered patients, inadequate healthcare coverage, and systemic pressure are factors influencing doctors’ test orders and…

54 minutes ago

IQM LAUNCHES INDUSTRY-FIRST NURSE TARGETING PRODUCT FOR HEALTHCARE CLIENTS

Powered by best-in-class data from Data360, IQM's Integrated Care Team Messaging allows brands to map…

59 minutes ago

Surgical Safety Technologies Announces Kinematic Data Integration to Transform Surgical Proficiency Assessment

NEW YORK, July 29, 2025 /PRNewswire/ -- Surgical Safety Technologies (SST), the global leader in…

59 minutes ago